| Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death AM van Harten, M Buijze, R van der Mast, MA Rooimans, ... Oncogenesis 8 (7), 38, 2019 | 60 | 2019 |
| Characterization of a head and neck cancer-derived cell line panel confirms the distinct TP53-proficient copy number-silent subclass AM van Harten, JB Poell, M Buijze, A Brink, SI Wells, CR Leemans, ... Oral Oncology 98, 53-61, 2019 | 26 | 2019 |
| Targeted treatment of head and neck (pre) cancer: preclinical target identification and development of novel therapeutic applications AM van Harten, RH Brakenhoff Cancers 13 (11), 2774, 2021 | 19 | 2021 |
| Chemopreventive targeted treatment of head and neck precancer by Wee1 inhibition AM van Harten, DV de Boer, SR Martens-de Kemp, M Buijze, ... Scientific reports 10 (1), 1-12, 2020 | 13 | 2020 |
| Gemcitabine as chemotherapy of head and neck cancer in Fanconi anemia patients AM van Harten, R Shah, DV de Boer, M Buijze, M Kreft, JY Song, ... Oncogenesis 13 (1), 26, 2024 | | 2024 |
| Targeting the cell cycle as treatment for head and neck cancer AM van Harten | | 2020 |
| Chk1 inhibition: a promising targeted treatment for head and neck squamous cell carcinoma AM van Harten, M Stigter-van Walsum, M Buijze, BJ Braakhuis, ... Cancer Research 76 (14 Supplement), 4637-4637, 2016 | | 2016 |
Rob WolthuisVUmc/CCA在 amsterdamumc.nl 的电子邮件经过验证
